Cancer Research The Future of Cancer Research: Science and Patient Impact  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 44, 1840-1842, May 1, 1984]
© 1984 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Koga, S.
Right arrow Articles by Osaki, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Koga, S.
Right arrow Articles by Osaki, Y.

Treatment of Implanted Peritoneal Cancer in Rats by Continuous Hyperthermic Peritoneal Perfusion in Combination with an Anticancer Drug1

Shigemasa Koga2, Ryuichi Hamazoe, Michio Maeta, Norio Shimizu, Hirotomo Kanayama and Yukio Osaki

Department of Surgery, Tottori University School of Medicine, 36-1 Nishimachi, Yonago 683, Japan

To study the feasibility of combined hyperthermic and anticancer drug treatment for peritoneal cancer, we devised a continuous hyperthermic peritoneal perfusion system in combination with mitomycin C. The model uses i.p.-transplantable rat ascites hepatoma 100B cells. Hyperthermic peritoneal perfusion alone or combined with mitomycin C was performed after i.p. inoculation of the tumor cells into rats. In rats treated with combined peritoneal perfusion (41.5°) and mitomycin C, the mean survival times were significantly prolonged as compared to those of rats treated with peritoneal perfusion at 41.5° alone. Our results suggest that combined hyperthermic peritoneal perfusion and mitomycin C treatment may represent a therapeutic and prophylactic treatment for peritoneal metastasis after gastric cancer surgery in humans.

1 Supported by a grant-in-aid for cancer research from the Japanese Ministry of Education and Culture (1981 and 1982).

2 To whom requests for reprints should be addressed.

Received 8/31/83. Accepted 2/ 2/84.




This article has been cited by other articles:


Home page
Ann OncolHome page
D. Elias, M. Bonnay, J. M. Puizillou, S. Antoun, S. Demirdjian, A. El Otmany, J. P. Pignon, L. Drouard-Troalen, J. F. Ouellet, and M. Ducreux
Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution
Ann. Onc., February 20, 2002; 13(2): 267 - 272.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1984 by the American Association for Cancer Research.